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Abstract: A synthetic route to novel chiral PNA monomer-cyclen conjugates was described for the first time, the targeted
products were obtained in high yields under mild reaction conditions. The preliminary results demonstrated that the uracil-PNA
monomer-cyclen conjugates can rapidly bind Zn2+ in aqueous solution, and the structure of the Zn(II) complex was confirmed
facilely by HRMS spectra, 1H NMR spectra and elemental analysis. Copyright  2005 European Peptide Society and John Wiley
& Sons, Ltd.
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INTRODUCTION
Peptide nucleic acid (PNA), reported in 1991 by Nielsen
[1,2], is an oligonucleotide analogue in which the
sugar-phosphate backbone is replaced by a polyamide
chain linked to the nucleobase (Figure 1). PNA offers
important advantages for the recognition of nucleic
acids including high-affinity binding, resistance to
degradation by nucleases or proteases, and a low
affinity for proteins [3,4]. Structural characterizations
[5,6] show that when PNA is complexed with a natural
nucleic acid the internal amide bonds of the PNA units
are uniformly aligned so that the carbonyl oxygens
of the tertiary amide bond point to the carboxy
terminus in an antiparallel Watson–Crick duplex.
Many derivatives and analogues of PNA composed
of N-(2-aminoethyl)glycine units were also designed
and prepared to improve their physico-chemical and
biological properties [7,8]. Recently the introduction
of chirality into the backbone has attracted much
attention [9–11]. Howarth and Wakelin reported that
α-PNAs, in which the thymine, cytosine, adenine
and guanine base-containing amino acid moieties are
derived from homoserine, are to modify the backbone
electrostatic charge, hydrophobicity and ridigity by
replacing glycine residues with appropriate amino acids
[9]. This study describes in detail the synthesis of a
uracil base-containing amino acid from L-cysteine and
their subsequent condensation with natural L-amino
acids to form a novel chiral uracil-PNA monomer. These
monomers can be conveniently conjugated with cyclen.
* Correspondence to: X-Q Yu, Department of Chemistry, Key Laboratory
of Green Chemistry and Technology (Ministry of Education), Sichuan
University, Chengdu 610064, P. R. China;
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1,4,7,10-Tetraazacyclododecane (cyclen) has become
an important building block for the synthesis of diag-
nostic and therapeutic pharmaceutical agents within
the past decade [12,13]. One of the fastest growing
medicinal uses of cyclen is in the development of MRI
contrast agents [13,14]. More recently, advances in
targeted cancer agents such as antibodies and pep-
tides have revived interest in cyclen-based bifunctional
chelating agents for therapy [15]. The mononuclear and
dinuclear Zn(II) complexes of cyclens are also found to
be efficient DNA cleavage agents [16–18].
In an effort to increase the specificity and to direct
the cleavage to within the minor groove of DNA, the
recognition and cleavage functions to DNA or RNA in
the same small molecule are desired greatly. This study
presents a type of novel chiral PNA monomer-cyclen
conjugates which may possibly combine the properties
of PNA and cyclen. The uracil as a recognition element
was linked to dipeptide to form chiral PNA monomers
and cyclen as a functional moiety was introduced to
construct the conjugates. To the best of our knowledge,
this is the first example of chiral PNA monomer-cyclen
conjugates.
MATERIALS AND METHODS
ESI-MS and HRMS spectra data were recorded on a Finni-
gan LCQDECA and a Bruker Daltonics Bio TOF mass
spectrometer respectively. The 1H NMR spectra were mea-
sured on a Varian INOVA-400 spectrometer and chemi-
cal shifts in ppm are reported relative to internal Me4Si
(CDCl3, DMSO-d6) or 3-(trimethylsilyl) propionic-2,2,3,3-d4
acid sodium salt (D2O). Elemental analyses were per-
formed using a Carlo-Elba 1106 elemental analytical instru-
ment. Polarimetric measurements were taken on a Perkin-
Elmer-341 automatic polarimeter. Melting points were deter-
mined using a micro-melting point apparatus and are
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Figure 1 Comparison of structure of DNA and PNA.
uncorrected. 5-Hydroxymethyluracil [19] and 1,4,7-tris (tert-
butyloxycarbonyl)-1,4,7,10-tetraazacyclododecance (3Boc-
cyclen) [20] were prepared according to the literature. All other
chemicals and reagents were obtained commercially and were
used without further purification.
S-Thyminyl-L-cysteine hydrochloride 3
A solution of L-cysteine hydrochloride (0.852 g, 6.00 mmol)
and 5-hydroxymethyluracil (0.942 g, 6.00 mmol) in 2 N HCl
(30 ml) was stirred at 50 °C for 48 h. After cooling, filter-
ing and evaporating, the S-thyminyl-L-cysteine hydrochlo-
ride was obtained as a white powder (1.59 g, 94%). Mp
238° –240 °C; [α]20D = +9.8 (c = 1.0, H2O); 1H NMR (400 MHz,
D2O): δ 7.64 (s, 1 H, uracil-6-CH), 4.36–4.33 (m, 1 H,
NH2CH), 3.59 (s, 2 H, S-CH2-uracil), 3.28–3.23 (m, 1 H,
NCHCH2S), 3.15–3.09 (m, 1 H, NCHCH2S); ESI-MS: m/z =
244.0 [M-1-HCl]−; HRMS (ESI) calcd for C8H11N3O4SNa [M +
Na-HCl]+: m/z = 268.0362. Found: 268.0355.
N-tert-Butyloxycarbonyl-S-thyminyl-L-cysteine 4
To an aqueous solution of sodium hydrogen carbon-
ate (1.68 g, 20.0 mmol); S-thyminyl-L-cysteine hydrochloride
(1.12 g, 4.00 mmol) in 1,4-dioxane (60 ml) was added. The
solution was then cooled to 0 °C with an ice bath. Di-t-
butyl carbonate (2.62 g, 12.0 mmol) dissolved in 1,4-dioxane
(20 ml) was added dropwise. After being kept at this temper-
ature for another 20 h, the solution was allowed to warm
to room temperature. The reaction mixture was concen-
trated under reduced pressure and the pH was adjusted
to 3–4 with 1 N KHSO4. After cooling and filtering, com-
pound 4 was obtained as a white powder (1.324 g, 96%).
Mp 118° –119 °C; [α]20D = +11.1 (c = 1.0, CH3OH); 1H NMR
(400 MHz, DMSO-d6): δ 12.82 (s, 1 H, COOH), 11.14 (s,
1 H, uracil-1-NH), 10.85 (s, 1 H, uracil-3-NH), 7.41 (s, 1 H,
uracil-6-CH), 6.92 (s, 1 H, OCONH), 4.04–3.99 (m, 1 H,
Boc-NHCH), 2.89–2.79 (m, 2 H, S-CH2-uracil), 2.73–2.65
(m, 2 H, NCHCH2S), 1.38 [s, 9 H, C(CH3)3]; ESI-MS: m/z =
344.4 [M-1]−; HRMS (ESI) calcd for C13H19N3O6SNa [M + Na]+:
m/z = 368.0887. Found: 368.0889.
General Procedure for the Preparation of 5
To a solution of N-tert-butyloxycarbonyl-S-thyminyl-L-cysteine
(1.03 g, 3.00 mmol) in anhydrous tetrahydrofuran (THF,
40 ml), N-methyl morphine (NMM) (0.390 ml, 3.30 mmol) and
i-C4H9OCOCl (0.402 ml, 3.00 mmol) were added sequentially
at about −15 °C. After 10 min a solution of L-amino acid
methyl ester (3.30 mmol) and NMM (0.390 ml, 3.30 mmol) in
anhydrous THF (60 ml) was poured into the reaction mixture.
The mixture was stirred for another 0.5 h at −15 °C and
left overnight at room temperature. After the solvent was
evaporated under reduced pressure, the solid residue was
dissolved in ethyl acetate and washed with saturated NaHCO3,
saturated brine and 2 N citric acid and the organic layer was
dried with anhydrous Na2SO4. After the solvent was removed,
the residue was purified by recrystallization from acetone and
ethyl ether. Compound 5 was obtained as a white powder.
5a: 1.136 g, 91%. Mp 199° –201 °C; [α]20D = +8.5 (c = 1.0,
CH3OH); 1H NMR (400 MHz, DMSO-d6): δ 11.15 (s,
1 H, uracil-1-NH), 10.82 (d, 1 H, J = 4.4 Hz, uracil-3-
NH), 8.37 (t, 1 H, J = 6.0 Hz, CONH), 7.40 (d, 1 H, J =
6.0 Hz, uracil-6-CH), 6.99 (d, 1 H, J = 8.8 Hz, OCONH),
4.18–4.12 (m, 1 H, Boc-NHCH), 3.86–3.83 (m, 2 H,
CH2COOCH3), 3.62 (s, 3 H, OCH3), 2.77–2.56 (m, 2 H,
S-CH2-uracil), 2.55–2.50 (m, 2 H, NCHCH2S), 1.38 [s,
9 H, C(CH3)3]; ESI-MS: m/z = 415.1 [M-1]−; HRMS (ESI)
calcd for C16H24N4O7SNa [M + Na]+: m/z = 439.1258.
Found: 439.1243.
5b: 1.317 g, 93%. Mp 205° –206 °C; [α]20D = +7.0 (c = 1.0,
CH3OH); 1H NMR (400 MHz, DMSO-d6): δ 11.16 (s,
1 H, uracil-1-NH), 10.84 (s, 1 H, uracil-3-NH), 8.24
(d, 1 H, J = 7.6 Hz, CONH), 7.41 (s, 1 H, uracil-6-CH),
6.98 (d, 1 H, J = 8.4 Hz, OCONH), 4.31–4.26 (m, 1 H,
CHCOOCH3), 4.15–4.10 (m, 1 H, Boc-NHCH), 3.60 (s,
3 H, OCH3), 2.74–2.56 (m, 2 H, S-CH2-uracil), 2.55–2.50
(m, 2 H, NCHCH2S), 1.64–1.54 (m, 2 H, CHCH2CH),
1.52–1.45 [m, 1 H, CH(CH3)2], 1.38 [s, 9 H, C(CH3)3],
0.89 (d, 3 H, J = 6.4 Hz, CHCH3), 0.83 (d, 3 H, J =
6.4 Hz, CHCH3); ESI-MS:m/z = 471.5 [M-1]−; HRMS (ESI)
calcd for C20H32N4O7SNa [M + Na]+: m/z = 495.1884.
Found: 495.1876.
5c: 1.378 g, 88%. Mp 128° –130 °C; [α]20D = +10.2 (c = 1.0,
CH3OH); 1H NMR (400 MHz, DMSO-d6): δ 11.17 (s, 1 H,
uracil-1-NH), 10.85 (d, 1 H, J = 4.8 Hz, uracil-3-NH),
9.24 (s, 1 H, Ph-OH), 8.21 (d, 1 H, J = 7.6 Hz, CONH),
7.41 (d, 1 H, J = 6.0 Hz, uracil-6-CH), 6.98 (d, 2 H,
J = 8.4 Hz, Ph-H), 6.94 (d, 1 H, J = 8.8 Hz, OCONH),
6.64 (d, 2 H, J = 8.4 Hz, Ph-H), 4.40–4.35 (m, 1 H,
CHCOOCH3), 4.17–4.11 (m, 1 H, Boc-NHCH), 3.56 (s, 3 H,
OCH3), 2.92–2.83 (m, 2 H, Ph-CH2), 2.71–2.54 (m, 2 H,
S-CH2-uracil), 2.51–2.49 (m, 2 H, NCHCH2S), 1.38 [s,
9 H, C(CH3)3]; ESI-MS: m/z = 521.1 [M-1]−; HRMS (ESI)
calcd for C23H30N4O8SNa [M + Na]+: m/z = 545.1677.
Found: 545.1689.
General Procedure for the Preparation of 6
Sodium hydroxide 2 N (5 ml, 10 mmol) was added slowly
dropwise to a suspension of compound 5 (2.00 mmol) in
methanol (20 ml) at 0 °C. The mixture was stirred for 2 h
at room temperature and the pH was adjusted to 7 with
1 N HCl. After removing most of the methanol, the pH was
adjusted to about 2. The mixture was then extracted with
ethyl acetate (3 × 30 ml) and the organic phase was dried with
anhydrous Na2SO4. After the solvent was evaporated under
reduced pressure, compound 6 was obtained as a white solid.
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6a: 0.764 g, 95%. Mp 195° –197 °C; [α]20D = +13.2 (c = 1.0,
CH3OH); 1H NMR (400 MHz, DMSO-d6): δ 12.60 (s, 1 H,
COOH), 11.13 (s, 1 H, uracil-1-NH), 10.83 (d, 1 H, J =
4.0 Hz, uracil-3-NH), 8.24 (t, 1 H, J = 5.6 Hz, CONH),
7.42 (d, 1 H, J = 5.6 Hz, uracil-6-CH), 6.95 (d, 1 H,
J = 8.8 Hz, OCONH), 4.19–4.14 (m, 1 H, Boc-NHCH),
3.80–3.72 (m, 2 H, CH2COOH), 2.79–2.54 (m, 2 H,
S-CH2-uracil), 2.51–2.49 (m, 2 H, NCHCH2S), 1.38 [s,
9 H, C(CH3)3]; ESI-MS: m/z = 401.0 [M-1]−; HRMS (ESI)
calcd for C15H22N4O7SNa [M + Na]+: m/z = 425.1101.
Found: 425.1099.
6b: 0.898 g, 98%. Mp 201° –203 °C; [α]20D = +9.3(c = 1.0,
CH3OH); 1H NMR (400 MHz, DMSO-d6): δ12.52 (s,
1 H, COOH), 11.13 (s, 1 H, uracil-1-NH), 10.79 (d,
1 H, J = 4.4 Hz, uracil-3-NH), 8.03 (d, 1 H, J = 8.0 Hz,
CONH), 7.41 (d, 1 H, J = 5.6 Hz, uracil-6-CH), 6.95
(d, 1 H, J = 8.4 Hz, OCONH), 4.27–4.20 (m, 1 H,
CHCOOH), 4.15–4.10 (m, 1 H, Boc-NHCH), 2.76–2.54
(m, 2 H, S-CH2-uracil), 2.52–2.49 (m, 2 H, NCHCH2S),
1.65–1.53 (m, 2 H, CHCH2CH), 1.52–1.44 [m, 1 H,
CH(CH3)2], 1.38 [s, 9 H, C(CH3)3], 0.89–0.82 [m, 6 H,
CH(CH3)2]; ESI-MS: m/z = 457.1 [M-1]−; HRMS (ESI)
calcd for C19H30N4O7SNa [M + Na]+: m/z = 481.1728.
Found: 481.1725.
6c: 0.996 g, 98%. Mp 101° –102 °C; [α]20D = +10.7 (c = 1.0,
CH3OH); 1H NMR (400 MHz, DMSO-d6): δ12.72 (s, 1 H,
COOH), 11.15 (s, 1 H, uracil-1-NH), 10.81 (d, 1 H,
J = 4.8 Hz, uracil-3-NH), 9.20 (s, 1 H, Ph-OH), 7.94
(d, 1 H, J = 7.6 Hz, CONH), 7.40 (d, 1 H, J = 5.6 Hz,
uracil-6-CH), 6.99 (d, 2 H, J = 8.4 Hz, Ph-H), 6.94 (d,
1 H, J = 8.8 Hz, OCONH), 6.62 (d, 2 H, J = 8.4 Hz,
Ph-H), 4.36–4.32 (m, 1 H, CHCOOH), 4.15–4.10 (m,
1 H, Boc-NHCH), 2.94–2.82 (m, 2 H, Ph-CH2), 2.78–2.54
(m, 2 H, S-CH2-uracil), 2.52–2.50 (m, 2 H, NCHCH2S),
1.38 [s, 9 H, C(CH3)3]; ESI-MS: m/z = 507.2[M-1]−;
HRMS (ESI) calcd for C22H28N4O8SNa [M + Na]+: m/z =
531.1521. Found: 531.1543.
General Procedure for the Preparation of 7
To a solution of compound 6 (1.00 mmol) in anhydrous THF
(20 ml), N-methyl morphine (NMM) (0.130 ml, 1.10 mmol) and
i-C4H9OCOCl (0.134 ml, 1.00 mmol) were added at about
−15 °C. After 10 min a solution of 3Boc-cyclen (0.472 g,
1.00 mmol) in anhydrous THF (30 ml) was poured into the
reaction mixture. The mixture was stirred for another 0.5 h at
−15 °C and left overnight at room temperature. The mixture
was then evaporated under reduced pressure to remove the
solvent. The solid residue was dissolved in ethyl acetate and
washed with saturated NaHCO3, saturated brine and 2 N
citric acid and the organic layer was dried with anhydrous
Na2SO4. After the solvent was evaporated, the residue was
purified by column chromatography on silica gel (eluent: ethyl
acetate/petroleum ether/acetone = 1 : 1 : 1, v/v/v) to afford
compounds 7 as a white solid.
7a: 0.565 g, 66%. Mp 134° –136 °C; [α]20D = +4.7 (c = 1.0,
CH3OH); 1H NMR (400 MHz, CDCl3): δ10.40 (s, 1 H,
uracil-1-NH), 10.24 (s, 1 H, uracil-3-NH), 7.59 (s,
1 H, CONH), 7.54 (s, 1 H, uracil-6-CH), 5.72 (d, 1 H,
J = 7.6 Hz, OCONH), 4.49–4.47 (m, 1 H, Boc-NHCH),
4.13–4.08 (m, 2 H, CH2CON), 3.53–3.40 (m, 16 H,
cyclen-CH2), 2.92–2.80 (m, 2 H, S-CH2-uracil), 2.52–2.50
(m, 2 H, NCHCH2S), 1.47–1.43 (m, 36 H, Boc-H);
ESI-MS: m/z = 855.5 [M-1]−; HRMS (ESI) calcd for
C38H64N8O12SNa [M + Na]+: m/z = 879.4257. Found:
879.4289.
7b: 0.584 g, 64%. Mp 137° –139 °C; [α]20D = +3.2 (c = 1.0,
CH3OH); 1H NMR (400 MHz, CDCl3): δ 10.46 (s, 1 H,
uracil-1-NH), 10.20 (s, 1 H, uracil-3-NH), 7.66 (s, 1 H,
CONH), 7.40 (s, 1 H, uracil-6-CH), 5.77 (d, 1 H, J =
7.6 Hz, OCONH), 4.81–4.70 (m, 1 H, CHCON), 4.52–4.47
(m, 1 H, Boc-NHCH), 3.72–3.40 (m, 16 H, cyclen-CH2),
2.75–2.68 (m, 2 H, S-CH2-uracil), 2.63–2.57 (m, 2 H,
NCHCH2S), 1.67–1.64 (m, 2 H, CHCH2CH), 1.62–1.51 [m,
1 H, CH(CH3)2], 1.46–1.42 (m, 36 H, Boc-H), 0.99–0.83
[m, 6 H, CH(CH3)2]; ESI-MS: m/z = 911.6 [M-1]−; HRMS
(ESI) calcd for C42H72N8O12SNa [M + Na]+: m/z =
935.4883. Found: 935.4896.
7c: 0.577 g, 60%. Mp 130° –131 °C; [α]20D = +4.3 (c = 1.0,
CH3OH); 1H NMR (400 MHz, CDCl3): δ 10.34 (s, 1 H,
uracil-1-NH), 10.22 (s, 1 H, uracil-3-NH), 7.80 (d, 1 H,
J = 8.0 Hz, CONH), 7.70 (d, 1 H, J = 8.0 Hz, uracil-6-CH),
7.37–7.30 (m, 2 H, Ph-H), 7.02–6.96 (m, 1 H, OCONH),
6.76–6.69 (m, 2 H, Ph-H), 5.02–5.00 (m, 1 H, CHCON),
4.42–4.39 (m, 1 H, Boc-NHCH), 3.70–3.17 (m, 16 H,
cyclen-CH2), 2.92–2.85 (m, 2 H, Ph-CH2), 2.76–2.72
(m, 2 H, S-CH2-uracil), 2.64–2.61 (m, 2 H, NCHCH2S),
1.45–1.42 (m, 36 H, Boc-H); ESI-MS: m/z = 961.4 [M-1]−;
HRMS (ESI) calcd for C45H70N8O13SNa [M + Na]+: m/z =
985.4675. Found: 985.4638.
General Procedure for the Preparation of 8
To a solution of compound 7 (0.500 mmol) in ethanol (10 ml),
47.5% aqueous HBr (5 ml) was added dropwise. After being
stirred at room temperature overnight, the reaction mixture
was concentrated under reduced pressure to give the crude
product, which was crystallized from ethanol/24% aqueous
HBr to afford compound 8 as a white powder.
8a: 0.303 g, 78%. Mp 188° –190 °C; [α]20D = +1.4 (c = 1.0,
H2O); 1H NMR (400 MHz, D2O): δ 7.67 (s, 1 H, uracil-
6-CH), 4.46–4.43 (m, 1 H, NH2CH), 4.30 (s, 2 H,
CH2CON), 3.82–3.29 (m, 16 H, cyclen-CH2), 3.25–3.19
(m, 2 H, S-CH2-uracil), 3.11–3.05 (m, 2 H, NCHCH2S);
ESI-MS: m/z = 455.2 [M-1-4HBr]−; Anal. Calcd for
C18H36N8O4Br4S: C, 27.71; H, 4.65; N, 14.36. Found:
C, 27.70; H, 4.86; N, 14.54.
8b: 0.329 g, 79%. Mp 243° –245 °C; [α]20D = +2.2 (c = 1.0,
H2O); 1H NMR (400 MHz, D2O): δ 7.71–7.68 (m, 1 H,
uracil-6-CH), 4.68–4.63 (m, 1 H, CHCON), 4.50–4.42 (m,
1 H, NH2CH), 3.82–3.27 (m, 16 H, cyclen-CH2), 3.26–3.17
(m, 2 H, S-CH2-uracil), 3.15–3.06 (m, 2 H, NCHCH2S)
1.84–1.73 (m, 2 H, CHCH2CH), 1.65–1.59 [m, 1 H,
CH(CH3)2], 1.05–1.00 [m, 6 H, CH(CH3)2]; ESI-MS:m/z =
511.3 [M-1-4HBr]−; Anal. Calcd for C22H44N8O4Br4S: C,
31.60; H, 5.30; N, 13.40. Found: C, 31.67; H, 5.24;
N, 13.62.
8c: 0.318 g, 72%. Mp 235° –236 °C; [α]20D = +2.9 (c = 1.0,
H2O); 1H NMR (400 MHz, D2O): δ 7.73–7.63 (m, 1 H,
uracil-6-CH), 7.25–7.20 (m, 2 H, Ph-H), 6.96–6.87 (m,
2 H, Ph-H), 4.66–4.54 (m, 1 H, CHCON), 4.48–4.39
(m, 1 H, NH2CH), 3.80–3.23 (m, 16 H, cyclen-CH2),
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Scheme 1 Synthetic route of uracil-PNA monomer-cyclen conjugates.
3.20–3.17 (m, 2 H, Ph-CH2), 3.14–3.07 (m, 2 H, S-CH2-
uracil), 3.04–2.97 (m, 2 H, NCHCH2S); ESI-MS: m/z =
561.3 [M-1-4HBr]−; Anal. Calcd for C25H42N8O5Br4S:
C, 33.88; H, 4.78; N, 12.64. Found: C, 33.69; H, 4.92;
N, 12.70.
General Procedure for the Preparation of Zinc(II)
Complex 9
To an aqueous solution (5 ml) of compound 8a (0.272 g,
0.350 mmol), an aqueous solution (5 ml) of Zn(ClO4)2·6H2O
(0.134 g, 0.360 mmol) was added slowly. The pH of the
solution was adjusted to 8–9 with 1 M NaOH. After being
stirred overnight, the reaction mixture was concentrated
under reduced pressure. The obtained residue was crystallized
from water to afford zinc(II) complex 9 as a white solid
(0.180 g, 83%). Mp 270° –272 °C; [α]20D = +2.5 (c = 1.0, H2O);
1H NMR (400 MHz, DMSO-d6): 10.23 (d, 1 H, J = 5.2 Hz,
uracil-3-NH), 7.50 (d, 1 H, J = 8.4 Hz, CONH), 7.18 (d, 1 H,
J = 5.6 Hz, uracil-6-CH), 6.13 (s, 2 H, NH2), 4.41–4.38 (m,
1 H, NH2CH), 4.22–4.17 (m, 2 H, CH2CO), 3.67–3.62 (m, 3 H,
CH2NHCH2), 3.51–3.20 (m, 16 H, cyclen-CH2), 2.95–2.80 (m,
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2 H, S-CH2-uracil), 2.51–2.49 (m, 2 H, NCHCH2S); HRMS
(ESI) calcd for C18H31N8O4SZn [M-ClO4]+: m/z = 519.1475.
Found: 519.1475; Anal. Calcd for C18H31N8O8ClSZn: C,
34.85; H, 5.04; N, 18.06. Found: C, 34.73; H, 5.06;
N, 17.92.
RESULTS AND DISCUSSION
Known methods for the synthesis of PNA monomers
rely on the use of protecting groups for the amino
function and for the nucleobases [9,21]. By using 5-
hydroxymethyluracil as a starting material, thio-PNA
monomer was obtained through the reaction of the
mercapto group on the side chain of L-cysteine with
the hydroxylmethyl group at the 5-position of uracil, so
in this study no protecting group was needed for the
nucleobases. Treatment of L-cysteine hydrochloride 1
with 5-hydroxymethyluracil 2 in 2 N HCl produced the
L-cysteine derivative 3 in 94% yield (Scheme 1). After
the protection of the amino group of 3 with a Boc group,
the dipeptides 5a–c were afforded conveniently in high
yield via the condensation of N-tert-butyloxycarbonyl-
S-thyminylcysteine 4 with L-amino acid methyl ester
hydrochloride in the presence of N-methyl morphine
(NMM) and i-C4H9OCOCl. The compounds 5a–c were
then saponified with 2 N sodium hydroxide (and the
reactions were monitored by TLC). The use of 5 equiv, of
NaOH can make the saponification reaction speedly and
complete. After the reaction mixtures were neutralized
to pH = 7 with 1 N HCl, compounds 6a–c were obtained
in approximately quantitative yields and followed by
condensation with 1,4,7-tris (tert-butyloxycarbonyl)-
1,4,7,10-tetraazacyclododecance (3Boc-cyclen) to give
the cyclen-conjugated dipeptides 7a–c in the presence
of N-methyl morphine (NMM) and i-C4H9OCOCl in high
yields. The Boc protective groups in 7a–c were removed
synchronously by 47.5% HBr in ethanol to give the
desired product PNA monomer-cyclen conjugates 8a–c
in over 70% yield. It was also found that compounds
8a (as free base) can rapidly bind Zn2+ in aqueous
solution. As outlined in Scheme 2, compound 8a was
conveniently converted to the zinc(II) complex of uracil-
PNA monomer-cyclen conjugate 9 in 83% yield. The
structure of complex 9 was confirmed facilely by
HRMS spectra (Figure 2), 1H NMR spectra (Figure 3)
and elemental analysis.
In summary, a synthetic route was developed to a
novel uracil-PNA monomer appended with 1,4,7,10-
tetraazacyclododecane, which will be used to pro-
duce PNA analogue oligomers containing special-site-
substituted nucleobases as a nucleic acid mimic.
Preliminary results demonstrated that the uracil-PNA
monomer-cyclen conjugates can rapidly bind Zn2+ in
aqueous solution, and the structure of the Zn(II) com-
plex was confirmed facilely by HRMS spectra, 1H NMR
spectra and elemental analysis. The synthesis of the
proposed oligomer and their hybridization properties
will be reported in due course.
Scheme 2 Synthesis of zinc(II) complex of uracil-PNA monomer-cyclen conjugate 8a.
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Figure 2 HRMS(ESI+) spectrum of (a) 8a (457.2340 in theory); (b) zinc(II) complex 9 (519.1475 in theory).
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Figure 3 Spectral changes of amide-NH of uracil in 1H NMR
spectrum: (a) 8a; (b) zinc(II) complex 9.
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